The Food and Drug Administration (FDA) has approved a new maintenance dosing schedule for Leqembi, a monoclonal antibody ...

A major trial in frontotemporal dementia patients has found that oxytocin can help improve symptoms of apathy. A new study ...

Access to the new Alzheimer's drugs is limited by strict eligibility criteria, long wait times, and a lack of infusion ...

Scientists have developed two new imaging agents that work better than the only currently approved one for detecting tau ...

Two new medications, called lecanemab and donanemab, have shown success in clinical trials in slowing down Alzheimer’s disease. These are known as disease-modifying treatments and have been licensed ...

For years, scientists have focused on amyloid beta buildup as the main culprit in Alzheimer’s disease, but a new study suggests the real problem might lie in a stalled protein-cutting process in the ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and (Nasdaq: BIIB, Corporate headquarters: Cambridge, ...

Revolutionary nasal spray offers hope by potentially delaying Alzheimer's progression through cutting-edge neurological ...

The next Alzheimer’s treatment could come from an unexpected place. In new research released this week, scientists have found ...

New drug approvals and a federal dementia care pilot program among the year's significant developments, according to the ...

or mild dementia due to AD, offers two dosing schedules. After an initial phase of once every two weeks for 18 months, patients can transition to the four-week dosing regimen. The FDA’s decision is ...

Alzheimer's disease, a devastating neurodegenerative condition that impacts millions globally, may have found an unexpected ...